Management of Candida auris Wound Infection After Previous Clearance
This patient requires immediate antifungal treatment with an echinocandin as first-line therapy, combined with aggressive infection control measures including contact precautions and environmental decontamination, regardless of her previous colonization clearance status.
Treatment Approach
Antifungal Therapy
The wound infection represents active C. auris disease requiring systemic treatment. Based on the most recent global guidance 1, echinocandins are the recommended first-line treatment for all forms of invasive candidiasis due to their broad activity and safety profile. For this patient:
- Start an echinocandin immediately:
- Caspofungin: 70 mg loading dose, then 50 mg daily
- Anidulafungin: 200 mg loading dose, then 100 mg daily
- Micafungin: 100 mg daily
Recent data confirms echinocandins maintain >90% susceptibility against C. auris, while fluconazole resistance exceeds 77% 2. The 2025 global guideline specifically addresses C. auris as an emerging pathogen requiring echinocandin therapy 1, superseding older recommendations that did not cover this organism 3.
Duration and Monitoring
Continue treatment until:
- Complete wound healing occurs
- All clinical signs and symptoms resolve
- Consider 2 weeks after documented clearance if systemic involvement is suspected 3
Obtain antifungal susceptibility testing on the wound isolate, as reduced echinocandin susceptibility can occur, though it remains uncommon 4, 2.
Critical Infection Control Measures
Do not assume this patient remains clear of colonization. The fact that she previously cleared colonization is clinically irrelevant now that she has active infection 5.
Immediate Actions Required:
Implement strict contact precautions - C. auris spreads readily person-to-person and via environmental surfaces 6, 7
Notify public health authorities immediately - This is a reportable pathogen requiring coordinated response 7
Perform comprehensive screening:
Environmental decontamination:
Understanding Recolonization vs. Persistent Infection
While some patients can clear C. auris colonization (median 8.6 months in one cohort, with 62% becoming serially negative) 5, active wound infection indicates current disease requiring treatment, not just colonization. The distinction is critical:
- Colonization = organism present without tissue invasion (may not require treatment)
- Infection = tissue invasion with clinical disease (requires antifungal therapy)
This patient has crossed from colonization to infection, which occurs more frequently in those with ≥5 comorbidities, ≥4 invasive devices, ≥3 recent procedures, or poor functional status 10.
Common Pitfalls to Avoid
Do not use fluconazole - Over 90% of C. auris isolates are fluconazole-resistant 6, 2
Do not assume previous clearance means current clearance - Recolonization can occur, and this patient now has active infection regardless 5, 9
Do not delay treatment for susceptibility results - Start empiric echinocandin immediately while awaiting testing 1
Do not use standard Candida identification methods - C. auris requires MALDI-TOF MS with appropriate reference databases or molecular testing for accurate identification 6
Do not discontinue contact precautions prematurely - Evidence is lacking on optimal duration, but transmission risk remains high throughout treatment 9
Assessment for Disseminated Disease
Given the high mortality associated with C. auris infections 1, 11, evaluate for:
- Blood cultures (even if wound is the only apparent site)
- Signs of candidemia or septic shock
- Presence of invasive devices (central lines, urinary catheters) that should be removed if feasible 3
The multipronged approach of immediate echinocandin therapy, aggressive infection control, contact screening, and environmental decontamination is essential for both individual patient outcomes and preventing healthcare facility transmission 1, 7.